Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches

touchFOCUS for touchONCOLOGY

Listen to Dr Dana Chase discuss the role of HER2 as a pan-tumour biomarker and the implications for treatment across various cancer types.

The expert

• Dr Dana Chase - UCLA Health, Los Angeles, CA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/